Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RANK ligand.

J M Blair1, Y Zheng, C R Dunstan

  • 1Molecular Bone Biology Laboratory, ANZAC Research Institute, University of Sydney at Concord Repatriation General Hospital, 1A Hospital Road, Concord, Sydney, NSW 2139, Australia. jblair@med.usyd.edu.au

The International Journal of Biochemistry & Cell Biology
|December 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soil net nitrogen mineralisation across global grasslands.

Nature communications·2019
Same author

Author Correction: Crowther et al. reply.

Nature·2018
Same author

Crowther et al. reply.

Nature·2018
Same author

Quantifying global soil carbon losses in response to warming.

Nature·2016
Same author

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab.

International journal for numerical methods in biomedical engineering·2013
Same author

Unique microstructural design of ceramic scaffolds for bone regeneration under load.

Acta biomaterialia·2013
Same journal

Corrigendum to "Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels" [Int. J. Biochem. Cell Biol. 42 (2010) 1840-1846].

The international journal of biochemistry & cell biology·2026
Same journal

Whole-brain spatial metabolomics reveals metabolic gradient shifts in a murine glioma model following boron neutron capture therapy (130 characters).

The international journal of biochemistry & cell biology·2026
Same journal

LCN2 modulates Th17/Treg balance in vitro and is associated with an adaptive response to intestinal ischemia-reperfusion injury under Hmox1-deficient conditions.

The international journal of biochemistry & cell biology·2026
Same journal

Chloroquine modulates the redox-sensitive signalling via inhibiting the AMPK-ULK1 under LPS induced state in murine splenic macrophages.

The international journal of biochemistry & cell biology·2026
Same journal

The vicious cycle of hyperglycemia and oxidative stress: Novel mechanistic insights into a pathogenic alliance.

The international journal of biochemistry & cell biology·2026
Same journal

Fibroblast growth factors (FGF) in the pathogenesis and treatment of inflammatory bowel diseases (IBD): An overview.

The international journal of biochemistry & cell biology·2026
See all related articles

Receptor activator of nuclear factor kappa-B ligand (RANKL) drives bone resorption by stimulating osteoclasts. Targeting RANKL offers therapeutic potential for bone diseases like osteoporosis and metastasis.

Area of Science:

  • Bone biology
  • Cell signaling
  • Endocrinology

Background:

  • Receptor activator of nuclear factor kappa-B ligand (RANKL) is crucial for bone resorption.
  • RANKL interacts with its receptor RANK to regulate osteoclast formation and activity.
  • Osteoprotegerin (OPG) acts as a decoy receptor, inhibiting RANKL signaling.

Purpose of the Study:

  • To review the central role of RANKL in bone resorption.
  • To discuss the therapeutic targeting of RANKL in various bone pathologies.

Main Methods:

  • Literature review of RANKL's function and therapeutic applications.
  • Analysis of RANKL's involvement in normal bone turnover and disease states.
  • Examination of RANKL's interaction with RANK and OPG.

Related Experiment Videos

Main Results:

  • RANKL stimulates osteoclast formation and activity, essential for bone resorption.
  • Dysregulation of RANKL/RANK/OPG signaling is implicated in bone diseases.
  • Therapeutic strategies targeting RANKL are effective for osteoporosis and bone metastases.

Conclusions:

  • RANKL is a pivotal regulator of bone resorption.
  • Targeting the RANKL pathway holds significant therapeutic promise for bone diseases.
  • Understanding RANKL signaling is key to developing novel treatments for skeletal disorders.